- Posted April 08, 2014
- Tweet This | Share on Facebook
Supreme Court takes up drug company dispute
![](/Content/LegalNews/images/article_db_image1.jpg)
WASHINGTON (AP) -- The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed last week to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
A federal district court had earlier ruled in Teva's favor and upheld the patents. Teva says the federal circuit should have deferred to factual findings made in the district court.
The justices will hear the case in the fall.
Published: Tue, Apr 8, 2014
headlines Oakland County
- Whitmer signs gun violence prevention legislation
- Department of Attorney General conducts statewide warrant sweep, arrests 9
- Adoptive families across Michigan recognized during Adoption Day and Month
- Reproductive Health Act signed into law
- Case study: Documentary highlights history of courts in the Eastern District
headlines National
- SCOTUSblog founder Tom Goldstein accused of transferring millions in cryptocurrency after tax indictment
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- Florida lawyer accused of stalking another attorney, texting rap songs with threatening lyrics
- Wisdom Through Face Paint: Documentary examines Juggalo gang allegations by DOJ
- No. 42 law firm by head count could face sanctions over fake case citations generated by ChatGPT
- Judge apologizes to slain jogger Ahmaud Arbery’s family after tossing charges against district attorney